Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
David Tougeron
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
David Tougeron
61 views
September 27, 2024
Login to view comments.
Click here to Login